Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Atrys Health's Enterprise Value is €440.6 Mil.
Atrys Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-33.0 Mil. Therefore, Atrys Health's EV-to-EBIT ratio for today is -13.36.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Atrys Health's Enterprise Value is €440.6 Mil.
Atrys Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.8 Mil. Therefore, Atrys Health's EV-to-EBITDA ratio for today is -49.99.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Atrys Health's Enterprise Value is €440.6 Mil.
Atrys Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €185.7 Mil. Therefore, Atrys Health's EV-to-Revenue ratio for today is 2.37.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Atrys Health's Enterprise Value is €440.6 Mil.
Atrys Health's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-14.1 Mil. Therefore, Atrys Health's EV-to-FCF ratio for today is -31.30.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Atrys Health (XMAD:ATRY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Atrys Health's current Enterprise Value is €440.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Atrys Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-33.0 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Atrys Health's current Enterprise Value is €440.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Atrys Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.8 Mil.
Atrys Health's current Enterprise Value is €440.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Atrys Health's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €185.7 Mil.
Atrys Health's current Enterprise Value is €440.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Atrys Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.6 Mil.
Atrys Health's current Enterprise Value is €440.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Atrys Health's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-14.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrys Health Enterprise Value Related Terms
Atrys Health Enterprise Value Historical Data
* Premium members only.
The historical data trend for Atrys Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Atrys Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Atrys Health's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Atrys Health's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrys Health (XMAD:ATRY) has a Enterprise Value of €440.6 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Atrys Health and its competitors.
Is Atrys Health's Enterprise Value too high?
Atrys Health's current Enterprise Value is €440.6 Mil. Overall, Atrys Health has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Enterprise Value compare to VRTX and REGN?
Atrys Health's Enterprise Value of €440.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Atrys Health and its competitors. Atrys Health's current Enterprise Value is €440.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.58 — trading 17% below its estimated fair value. The current Enterprise Value is €440.6 Mil. Atrys Health's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Enterprise Value is €440.6 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.58 is trading 17% below its estimated GF Value™ of €3.11.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
Enterprise Value: €440.6 Mil
GF Value™: €3.11 vs. price of €2.58 (17% below fair value)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
68GF Score
Get the complete analysis for XMAD:ATRY
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
